-
Your selected country is
Poland
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Profile of peripheral blood granulocytes analyzed on a FACScan (BDIS, San Jose, CA)
BD Pharmingen™ PE Mouse Anti-Human CD221
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
The 1H7 monoclonal antibody specifically binds to the α subunit of the human insulin-like growth factor-I (IGF-I) receptor that is also known as CD221. CD221 is a receptor tyrosine kinase that has high affinity for IGF-1 and low affinity for insulin and IGF-2. CD221 is synthesized as a 180 kDa precursor molecule that is processed into two subunits, a 135 kDa α subunit which is disulfide-linked to a 90 kDa β subunit. The mature IGF-IR complex is comprised of two extracellular α subunits and two transmembrane β subunits that each possesses a tyrosine kinase domain. When bound by ligand, the IGF-1 receptor autophosphorylates multiple tyrosine sites in its β chains and phosphorylates other signaling molecules that regulate cell growth, development, and neoplastic transformation. CD221 is structurally and functionally similar to the insulin receptor (aka, CD220) and is expressed on a variety of human hematopoietic and non-hematopoietic cells. The 1H7 antibody does not crossreact with the human insulin receptor and can block IGF-I- or IGF-II-stimulated cell growth.
Development References (3)
-
Kooijman RK, Scholtens LE, Rijkers GT, Zegers BJ. Differential expression of type I insulin-like growth factor receptors in different stages of human T cells. Eur J Immunol. 1995; 25(4):931-935. (Biology). View Reference
-
Li SL, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y. Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun. 1993; 196(1):92-98. (Biology). View Reference
-
Xiong L, Kasuya J, Li SL, Kato J, Fujita-Yamaguchi Y. Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor. Proc Natl Acad Sci U S A. 1992; 89(12):5356-5360. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.